Riskpilot← Back to searchSign inGet full accessFURST NAT AS
ASActiveOrg 985452865Medisinske laboratorietjenester · NACE 86906Est. 20035 employees
Revenue 2021
NOK 44,3M
+252% vs 2020
EBITDA margin
28.9%
+5162% vs 2020
Equity ratio
17.8%
Financial strength
Net profit 2021
NOK 9,7M
+2284% vs 2020
| Revenue | NOK 44,3M | +252% |
| EBITDA | NOK 12,8M | +5162% |
| Net profit | NOK 9,7M | +2284% |
| Total assets | NOK 36,6M | +347% |
| Equity | NOK 6,5M | +13% |
| Employees | 5 | — |
Legal name
FURST NAT AS
Org number
985452865
Legal form
Aksjeselskap
NACE code
86906 · Medisinske laboratorietjenester
Founded
4. mars 2003
Share capital
NOK 290 000 000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller to styremedlemmer i fellesskap.
Company purpose
Medisinsk analysevirksomhet primært med utgangspunkt i genteknologiske metoder, samt deltagelse i annen virksomhet eller selskaper og garantistillelse med tilknytning til dette.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 394 | 7 255 | 9 619 | 14 658 | 8 849 | 12 853 | 18 404 | 16 839 | 17 698 | 18 410 | 15 960 | 14 044 | 12 591 | 44 276 |
| Staff expenses | 3 152 | 3 411 | 3 735 | 4 171 | −3 532 | −4 050 | −4 556 | −4 401 | −4 297 | −4 434 | −4 980 | −5 300 | −5 167 | −6 557 |
| EBITDA | −2 357 | −1 619 | −631 | 2 598 | 2 464 | 4 853 | 7 619 | 6 947 | 6 862 | 6 638 | 3 967 | 162 | −252 | 12 776 |
| Depreciation & amort. | 536 | 477 | 543 | 392 | −113 | −135 | −265 | −392 | −458 | −475 | −437 | −399 | −347 | −323 |
| EBIT | −1 821 | −1 142 | −87 | 2 990 | 2 351 | 4 718 | 7 353 | 6 555 | 6 404 | 6 163 | 3 530 | −238 | −600 | 12 453 |
| Net financials | 138 | 44 | 48 | 113 | 146 | 141 | 188 | 122 | 88 | 114 | 127 | 92 | 28 | 19 |
| Profit before tax | −1 683 | −1 098 | −40 | 3 103 | 2 496 | 4 860 | 7 541 | 6 677 | 6 492 | 6 276 | 3 657 | −146 | −572 | 12 471 |
| Tax | −471 | −310 | −34 | 861 | 696 | 1 363 | 2 000 | 1 807 | 1 624 | 1 509 | 845 | −32 | −126 | 2 744 |
| Net profit | −1 212 | −788 | −5 | 2 242 | 1 801 | 3 497 | 5 541 | 4 870 | 4 868 | 4 767 | 2 812 | −113 | −445 | 9 728 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 739 | 5 918 | 6 532 | 10 272 | 10 360 | 15 675 | 15 025 | 13 715 | 14 540 | 19 541 | 11 379 | 8 157 | 8 184 | 36 574 |
| Equity | 4 722 | — | — | 6 978 | 8 779 | 6 275 | 5 816 | 6 186 | 11 054 | 15 822 | 5 822 | 5 776 | 5 772 | 6 499 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 017 | 1 177 | 1 797 | 3 294 | 1 582 | 9 399 | 9 209 | 7 529 | 3 485 | 3 719 | 5 557 | 2 380 | 2 412 | 30 075 |
| Total debt | 2 017 | 1 177 | 1 797 | 3 294 | 1 582 | 9 399 | 9 209 | 7 529 | 3 485 | 3 719 | 5 557 | 2 380 | 2 412 | 30 075 |
EBITDA margin
28.9%
This company
15.8%
Market median
+83% vs market
20082021
Equity ratio
17.8%
This company
38.2%
Market median
-53% vs market
20082021
Return on equity
149.7%
This company
18.4%
Market median
+714% vs market
20082021
Net profit margin
22.0%
This company
8.1%
Market median
+172% vs market
20082021
Asset turnover
1.21×
This company
1.12×
Market median
+8% vs market
20082021
Debt / equity
4.63×
This company
0.62×
Market median
-647% vs market
20082021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Contact Person | Contact Person | 2003 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dr Furst Medisinsk Laboratorium As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ferd Lab Invest As
FURST NAT AS Board members of FURST NAT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Asle Helgheim | Contact Person | 0 companies |
| Håvard Selby Ebbestad | Chairman | 0 companies |